Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen
European Journal of Haematology · 2025-04 · 114 (4) · 626-635
DOI: 10.1111/ejh.14371 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 26.12.2024. Verfasst von Margaret Rowe und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Tumor Lysis Syndrome, Leukemia, Myeloid, Acute, Bridged Bicyclo Compounds, Heterocyclic, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Venetoclax with hypomethylating agents (HMA) is the standard of care for acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy and is associated with tumor lysis syndrome (TLS). TLS prophylaxis and the use of Cairo Bishop versus Howard diagnostic criteria are not standardized. Here we report TLS prophylaxis and incidence in a retrospective cohort of 100 consecutive AML patients treated with venetoclax and HMA. Thirty four patients developed laboratory Cairo Bishop TLS; 8 of these met criteria for clinical Cairo Bishop TLS. Only 6 of patients met Howard TLS criteria. Fourteen patients had spontaneous TLS. Ninety two out of 100 patients had a white blood cell count (WBC) < 25 000 cells/μL at treatment start. Prophylaxis like the original venetoclax trial with allopurinol (56%), intravenous fluids (21%), and frequent lab monitoring (56%) was less common. There was a trend toward increased Cairo Bishop TLS in patients with WBC ≥ 15 000 cells/μL. In our study Howard TLS criteria better identified patients with significant TLS. Aggressive TLS prophylaxis was uncommon in our cohort and is likely unnecessary for most patients at low risk of TLS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Division of Hematology and Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Margaret Rowe
Zitieren
APA
Rowe, M., Babushok, D., Carroll, M., Carulli, A., Frey, N., Gill, S., Hexner, E., Hirsh, R., Hossain, N., Lai, C., Loren, A., Luger, S., Maillard, I., McCurdy, S., Matthews, A., Martin, M. E., Paralkar, V. R., Perl, A., Porter, D., …, & Bruno, X. J. (2025). Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen. European Journal of Haematology, 114(4), 626-635. https://doi.org/10.1111/ejh.14371
Vancouver
Rowe M, Babushok D, Carroll M, Carulli A, Frey N, Gill S, et al. Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen. European Journal of Haematology. 2025;114(4):626-635. doi:10.1111/ejh.14371
BibTeX
@article{Rowe2025,
author = {Rowe, Margaret and Babushok, Daria and Carroll, Martin and Carulli, Alison and Frey, Noelle and Gill, Saar and Hexner, Elizabeth and Hirsh, Rebecca and Hossain, Nasheed and Lai, Catherine and Loren, Alison and Luger, Selina and Maillard, Ivan and McCurdy, Shannon and Matthews, Andrew and Martin, Mary Ellen and Paralkar, Vikram R and Perl, Alexander and Porter, David and Pratz, Keith and Stadtmauer, Edward and Bruno, Ximena Jordan},
title = {Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen},
journal = {European Journal of Haematology},
year = {2025},
volume = {114},
number = {4},
pages = {626--635},
doi = {10.1111/ejh.14371}
}
EUVIMED